Physician profile
Mark S Hernandez
NPI 1093783490
$2,923.37
in general payments reported to CMS, 2019-2025
19 companies · $1,226 in 2025
The $1,226 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $497 · 2024: $1,201 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,903 · Education: $19.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,903.42 |
| Education | $19.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $868.65 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $839.34 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $475.59 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.42 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $104.71 | 2023-2025 | Veozah |
| Pfizer INC. | $90.34 | 2024-2025 | |
| Abbott Laboratories | $54.94 | 2023-2025 | Proclaim, Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $53.52 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $43.56 | 2024-2025 | Tezspire, Airsupra |
| Axsome Therapeutics, INC. | $42.09 | 2023-2025 | Auvelity |
| Sanofi Pasteur INC. | $34.43 | 2024 | |
| Exact Sciences Corporation | $34.19 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $32.74 | 2024-2025 | |
| Amgen INC. | $25.15 | 2025 | Repatha |
| Merck Sharp & Dohme LLC | $24.99 | 2025 | Gardasil 9, Capvaxive |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $22.36 | 2024 | Teriparatide |
| Seqirus USA INC | $16.05 | 2025 | Flucelvax, Fluad |
| Sumitomo Pharma America, INC. | $15.28 | 2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $14.02 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.